文献速递浆细胞疾病

达雷妥尤单抗、来那度胺和地塞米松治疗既往接受过治疗的多发性骨髓瘤(POLLUX)的总生存期:一项随机、开放标签、III期试验

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
PubMed 文献 · J Clin Oncol · 2023-01-04

POLLUX研究在多中心随机开放标签III期试验中比较D-Rd与Rd方案治疗复发或难治性多发性骨髓瘤,中位随访79.7个月时D-Rd组总生存期显著优于Rd组(风险比0.73,95%CI 0.58-0.91,P=0.0044),中位总生存期67.6个月对51.8个月。

要点

  • D-Rd方案较Rd方案显著延长复发或难治性多发性骨髓瘤患者的总生存期(HR 0.73,95%CI 0.58-0.91,P=0.0044)。
  • D-Rd组中位总生存期为67.6个月,Rd组为51.8个月。
  • D-Rd组最常见的≥10%的3/4级治疗中出现的不良事件包括中性粒细胞减少(57.6%对41.6%)、贫血(19.8%对22.4%)、肺炎(17.3%对11.0%)。

核心结论

  • D-Rd方案较Rd方案显著延长复发或难治性多发性骨髓瘤患者的总生存期。
  • 据作者所知,本研究发现连同III期CASTOR试验中达雷妥尤单抗联合硼替佐米和地塞米松观察到的总生存获益,首次证明含达雷妥尤单抗方案可改善复发或难治性多发性骨髓瘤的总生存。

研究设计与样本

  • POLLUX为多中心、随机、开放标签、III期研究,纳入至少接受过1线既往治疗的患者,按1:1随机分配至D-Rd或Rd组,治疗直至疾病进展或不可耐受的毒性。
  • 阳性主要分析及方案修订后,Rd组疾病进展患者可接受达雷妥尤单抗单药治疗。

主要发现

  • 在中位(范围)随访79.7个月(0.0-86.5)时,D-Rd组较Rd组观察到显著总生存获益(风险比0.73,95%CI 0.58-0.91,P=0.0044)。
  • D-Rd组中位总生存期为67.6个月,Rd组为51.8个月。
  • 预设分析显示,在大多数亚组中D-Rd较Rd改善总生存,包括年龄≥65岁患者以及既往接受过1、2或3线治疗、国际分期体系III期疾病、高危细胞遗传学异常、对末线既往治疗或蛋白酶体抑制剂难治的患者。
  • D-Rd组与Rd组最常见的(≥10%)3/4级治疗中出现的不良事件分别为中性粒细胞减少(57.6%对41.6%)、贫血(19.8%对22.4%)、肺炎(17.3%对11.0%)、血小板减少(15.5%对15.7%)和腹泻(10.2%对3.9%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: With the initial analysis of POLLUX at a median follow-up of 13.5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the time of final analysis for overall survival (OS). METHODS: POLLUX was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned 1:1 to D-Rd or Rd until disease progression or unacceptable toxicity. After positive primary analysis and protocol amendment, patients receiving Rd were offered daratumumab monotherapy after disease progression. RESULTS: Significant OS benefit was observed with D-Rd (hazard ratio, 0.73; 95% CI, 0.58 to 0.91; P = .0044) at a median (range) follow-up of 79.7 months (0.0-86.5). The median OS was 67.6 months for D-Rd compared with 51.8 months for Rd. Prespecified analyses demonstrated an improved OS with D-Rd versus Rd in most subgroups, including patients age ≥ 65 years and patients with one, two, or three prior lines of therapy, International Staging System stage III disease, high-risk cytogenetic abnormalities, and refractoriness to their last prior line of therapy or a proteasome inhibitor. The most common (≥ 10%) grade 3/4 treatment-emergent adverse events with D-Rd versus Rd were neutropenia (57.6% v 41.6%), anemia (19.8% v 22.4%), pneumonia (17.3% v 11.0%), thrombocytopenia (15.5% v 15.7%), and diarrhea (10.2% v 3.9%). CONCLUSION: D-Rd significantly extended OS versus Rd alone in patients with RRMM. To our knowledge, for the first time, our findings, together with the OS benefit observed with daratumumab plus bortezomib and dexamethasone in the phase III CASTOR trial, demonstrate OS improvement with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02076009 [POLLUX]).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Dimopoulos MA, Oriol A, Nahi H, et al. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023. PMID: 36599114. doi:10.1200/JCO.22.00940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。